Understanding Persistence and Overcoming Tumor-Immune Challenges

While adoptive cell transfer (ACT) is a promising therapeutic approach to fighting cancer, conventional delivery methods for this therapy include high doses of IL-2 to support the expansion and function of the transferred cells. However, this induces toxicity and immunosuppression, limiting the use of ACT. Researchers at UCLA created a novel agonist that increased proliferation, homing, and persistence of anti-tumor T cells in vivo.

Download this article from The Scientist’s Creative Services team and IsoPlexis to learn more about how UCLA researchers identified and created a novel agonist to outperform IL-2 for expanding transferred cells, increasing persistence, and improving anti-tumor response.